William E. Rote

CIK: 0001698262

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)15 (51.7%)

Position reduction

Option Exercises (M)9 (31.0%)

Derivative conversions

Awards (A)5 (17.2%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

TVTX

Travere Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (29 total)

TVTX
Travere Therapeutics, Inc.
Sep 16, 2026
Exercise(M)
Direct
350 shares at avg. $17.96$6K
TVTX
Travere Therapeutics, Inc.
Sep 16, 2026
Exercise(M)
Direct
55K shares at avg. $15.46$850K
TVTX
Travere Therapeutics, Inc.
Sep 16, 2026
Sale(S)
Direct
65.1K shares at avg. $63.12$4.1M
TVTX
Travere Therapeutics, Inc.
Sep 16, 2026
Exercise(M)
Direct
57.5K shares at avg. $26.88$1.5M
TVTX
Travere Therapeutics, Inc.
Sep 16, 2026
Sale(S)
Direct
47.7K shares at avg. $63.61$3.0M
TVTX
Travere Therapeutics, Inc.
Sep 15, 2026
Sale(S)
Direct
63.9K shares at avg. $61.99$4.0M
TVTX
Travere Therapeutics, Inc.
Sep 15, 2026
Sale(S)
Direct
3K shares at avg. $63.65$191K
TVTX
Travere Therapeutics, Inc.
Sep 15, 2026
Sale(S)
Direct
29K shares at avg. $62.66$1.8M
TVTX
Travere Therapeutics, Inc.
Sep 15, 2026
Sale(S)
Direct
270 shares at avg. $65.31$18K
TVTX
Travere Therapeutics, Inc.
Sep 15, 2026
Exercise(M)
Direct
39K shares at avg. $25.25$985K
TVTX
Travere Therapeutics, Inc.
Sep 15, 2026
Exercise(M)
Direct
39.7K shares at avg. $17.96$712K
TVTX
Travere Therapeutics, Inc.
May 6, 2026
Sale(S)
Direct
2.8K shares at avg. $43.95$121K
TVTX
Travere Therapeutics, Inc.
May 4, 2026
Award(A)
Performance-based restricted stock units
Direct
8.5K shares-
TVTX
Travere Therapeutics, Inc.
May 4, 2026
Exercise(M)
Direct
4.3K shares-
TVTX
Travere Therapeutics, Inc.
Apr 22, 2026
Sale(S)
Direct
9.1K shares at avg. $39.09$356K
TVTX
Travere Therapeutics, Inc.
Apr 13, 2026
Award(A)
Direct
14K shares-
TVTX
Travere Therapeutics, Inc.
Feb 3, 2026
Sale(S)
Direct
12.4K shares at avg. $32.87$409K
TVTX
Travere Therapeutics, Inc.
Jan 31, 2026
Award(A)
Direct
20.1K shares-
TVTX
Travere Therapeutics, Inc.
Dec 24, 2025
Sale(S)
Direct
60K shares at avg. $40.10$2.4M
TVTX
Travere Therapeutics, Inc.
Dec 24, 2025
Exercise(M)
Direct
60K shares at avg. $20.61$1.2M
TVTX
Travere Therapeutics, Inc.
May 5, 2025
Sale(S)
Direct
3.2K shares at avg. $21.05$67K
TVTX
Travere Therapeutics, Inc.
May 2, 2025
Exercise(M)
Direct
4.9K shares-
TVTX
Travere Therapeutics, Inc.
Feb 12, 2025
Sale(S)
Direct
5.2K shares at avg. $23.53$122K
TVTX
Travere Therapeutics, Inc.
Feb 10, 2025
Exercise(M)
Direct
8K shares-
TVTX
Travere Therapeutics, Inc.
Feb 3, 2025
Sale(S)
Direct
9K shares at avg. $19.78$177K

		Type	Shares	Price		Ownership
Sep 16, 2026	TVTX Travere Therapeutics, Inc.	Exercise(M)	350	$17.96	$6,286	Direct
Sep 16, 2026	TVTX Travere Therapeutics, Inc.	Exercise(M)	55,000	$15.46	$850,300	Direct
Sep 16, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	65,104	$63.12	$4,109,397	Direct
Sep 16, 2026	TVTX Travere Therapeutics, Inc.	Exercise(M)	57,500	$26.88	$1,545,600	Direct
Sep 16, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	47,746	$63.61	$3,037,247	Direct
Sep 15, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	63,907	$61.99	$3,961,851	Direct
Sep 15, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	3,000	$63.65	$190,952	Direct
Sep 15, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	29,021	$62.66	$1,818,317	Direct
Sep 15, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	270	$65.31	$17,634	Direct
Sep 15, 2026	TVTX Travere Therapeutics, Inc.	Exercise(M)	39,000	$25.25	$984,750	Direct
Sep 15, 2026	TVTX Travere Therapeutics, Inc.	Exercise(M)	39,650	$17.96	$712,114	Direct
May 6, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	2,763	$43.95	$121,434	Direct
May 4, 2026	TVTX Travere Therapeutics, Inc.	Award(A) Performance-based restricted stock units	8,500	-	-	Direct
May 4, 2026	TVTX Travere Therapeutics, Inc.	Exercise(M)	4,250	-	$0	Direct
Apr 22, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	9,100	$39.09	$355,719	Direct
Apr 13, 2026	TVTX Travere Therapeutics, Inc.	Award(A)	14,000	-	$0	Direct
Feb 3, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	12,446	$32.87	$409,100	Direct
Jan 31, 2026	TVTX Travere Therapeutics, Inc.	Award(A)	20,090	-	$0	Direct
Dec 24, 2025	TVTX Travere Therapeutics, Inc.	Sale(S)	60,000	$40.10	$2,406,180	Direct
Dec 24, 2025	TVTX Travere Therapeutics, Inc.	Exercise(M)	60,000	$20.61	$1,236,600	Direct
May 5, 2025	TVTX Travere Therapeutics, Inc.	Sale(S)	3,198	$21.05	$67,318	Direct
May 2, 2025	TVTX Travere Therapeutics, Inc.	Exercise(M)	4,920	-	-	Direct
Feb 12, 2025	TVTX Travere Therapeutics, Inc.	Sale(S)	5,200	$23.53	$122,356	Direct
Feb 10, 2025	TVTX Travere Therapeutics, Inc.	Exercise(M)	8,000	-	-	Direct
Feb 3, 2025	TVTX Travere Therapeutics, Inc.	Sale(S)	8,951	$19.78	$177,051	Direct

1-25 of 29 transactions

About ROTE WILLIAM E.

ROTE WILLIAM E. (SEC CIK 0001698262) files insider reports with the SEC as Chief Research Officer of Travere Therapeutics, Inc. (TVTX).

Signal8 holds 11 ownership filings by ROTE WILLIAM E., all Form 4s, filed between Sep 9, 2024 and Sep 17, 2026. Those filings report 29 transactions, from Sep 5, 2024 to Sep 16, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on ROTE WILLIAM E.'s filings is in SAN DIEGO, CA.

Recent filings by ROTE WILLIAM E.

Sep 16, 2026: Option exercises of TVTX shares (2 lines, Form 4, code M).
Sep 16, 2026: Open-market sale of TVTX shares (Form 4, code S).
Sep 16, 2026: Option exercise of TVTX shares (Form 4, code M).
Sep 16, 2026: Open-market sale of TVTX shares (Form 4, code S).
Sep 15, 2026: Open-market sales of TVTX shares (4 lines, Form 4, code S).

Other insiders filing for Travere Therapeutics, Inc. (TVTX)

Dube Eric M, CHIEF EXECUTIVE OFFICER
Heerma Peter, EVP, CHIEF COMMERCIAL OFFICER
Inrig Jula, EVP, Head of R&D & CMO
REED ELIZABETH E, Chief Legal Officer and GC
Cline Christopher R., CHIEF FINANCIAL OFFICER
Calvin Sandra, SVP, CHIEF ACCOUNTING OFFICER

How to read Form 4 transaction codes